MedTrace Logo

This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD).

NCT05935085 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 201

Last updated 2025-02-14

No results posted yet for this study

Summary

This study will evaluate the safety, tolerability, and efficacy of ANB032 in subjects with moderate to severe atopic dermatitis (AD).

Conditions

  • Atopic Dermatitis Eczema

Interventions

DRUG

ANB032

BTLA agonist antibody

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • AnaptysBio, Inc.

    lead INDUSTRY

Principal Investigators

  • Mark Rigby, MD · AnaptysBio, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-13
Primary Completion
2024-10-16
Completion
2025-01-07
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • Czechia
  • Georgia
  • New Zealand
  • Poland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05935085 on ClinicalTrials.gov